Wednesday, July 8, 2026

pharma · Hypercholesterolemia · Hyperlipidemia · ESPR

Esperion Therapeutics

Espervita Therapeutics is a pharma organization headquartered in ann arbor, USA. It trades on NYSE under ticker ESPR. Primary therapeutic focus areas include Hypercholesterolemia, Hyperlipidemia, Cardiovascular Diseases,

Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
Status
Public
HQ
Ann Arbor, US
Employees
5
Programs
15
Drugs
9
Patents
55
Clinical program

Bempedoic Acid / Ezetimibe Oral Tablet

Approved · small molecule · Cardiovascular Diseases

Bempedoic Acid / Ezetimibe Oral Tablet for Cardiovascular Diseases is a Approved program (small_molecule) at Esperion Therapeutics with 1 ClinicalTrials.gov record(s).

← All Esperion Therapeutics projects Approved small molecule active

Internal code 1824539

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Esperion Therapeutics
Phase
Approved
Modality
small_molecule
Indication
Cardiovascular Diseases
Status
active
Trials
1